$2.16
5.76% yesterday
Nasdaq, May 20, 09:50 pm CET
ISIN
US87583X1090
Symbol
TNGX

Tango Therapeutics Inc Stock price

$2.07
+0.69 50.00% 1M
-2.01 49.26% 6M
-1.02 33.01% YTD
-5.60 73.01% 1Y
-3.50 62.84% 3Y
-8.16 79.77% 5Y
-8.16 79.77% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.22 9.61%
ISIN
US87583X1090
Symbol
TNGX
Sector

Key metrics

Market capitalization $224.38m
Enterprise Value $44.18m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.08
P/S ratio (TTM) P/S ratio 5.47
P/B ratio (TTM) P/B ratio 1.34
Revenue growth (TTM) Revenue growth 10.10%
Revenue (TTM) Revenue $40.99m
EBIT (operating result TTM) EBIT $-145.87m
Free Cash Flow (TTM) Free Cash Flow $-135.95m
Cash position $217.15m
EPS (TTM) EPS $-1.21
P/E forward negative
P/S forward 7.83
EV/Sales forward 1.54
Short interest 14.02%
Show more

Is Tango Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Tango Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Tango Therapeutics Inc forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Tango Therapeutics Inc forecast:

Buy
100%

Financial data from Tango Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
41 41
10% 10%
100%
- Direct Costs 2.50 2.50
26% 26%
6%
39 39
14% 14%
94%
- Selling and Administrative Expenses 40 40
26% 26%
97%
- Research and Development Expense 142 142
14% 14%
347%
-143 -143
17% 17%
-350%
- Depreciation and Amortization 2.50 2.50
26% 26%
6%
EBIT (Operating Income) EBIT -146 -146
16% 16%
-356%
Net Profit -132 -132
18% 18%
-323%

In millions USD.

Don't miss a Thing! We will send you all news about Tango Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tango Therapeutics Inc Stock News

Neutral
GlobeNewsWire
9 days ago
– Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 – – Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 – – Cash position of $217 million as of March 31, 2025; cash runway extended into 1Q 2027 with reduction of preclinical spend –   BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), ...
Neutral
GlobeNewsWire
20 days ago
BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call.
Neutral
GlobeNewsWire
about 2 months ago
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been accepted as poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 20...
More Tango Therapeutics Inc News

Company Profile

Tango Therapeutics, Inc. operates as a biotechnology company that engages in discovering and delivering precision cancer medicines. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Cambridge, MA.

Head office United States
CEO Barbara Weber
Employees 155
Founded 2017
Website www.tangotx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today